-
Atmo Biosciences named winner in Fast Company’s 2026 World Changing Ideas Awards
16 June 2026. Atmo Biosciences is proud to announce that it has been named a winner of Fast Company’s 2026 World Changing Ideas Awards. This annual recognition honors bold and transformative efforts...
-
Atmo Biosciences Receives FDA Clearance for Gastrointestinal (GI) Contractility Frequency Map
26 May 2026. Atmo Biosciences is delighted to announce that we have just received US Food and Drug Administration (FDA) 510(k) clearance for a new Contractility Frequency Map feature as an enhancement...
-
Atmo Biosciences receives US FDA clearance for ingestible gas-sensing capsule.
27 June 2025. Atmo Biosciences is delighted to announce that it has received US Food and Drug Administration (FDA) 510(k) clearance for the Atmo Gas Capsule System, paving the way for its first produc...
April 15, 2025
Atmo Biosciences Strengthens IP Portfolio with Assignment of Patents from RMIT University.
Atmo Biosciences today announced the successful assignment of its foundational patent portfolio from RMIT University. Under this agreement, RMIT has transferred all patents and associated intellectual property (IP) related to the Atmo Gas Capsule to Atmo Biosciences in exchange for an equity stake in the company. This IP was previously subject to an exclusive royalty-based license agreement between Atmo and RMIT.
March 4, 2025
Atmo Biosciences announces publication of pivotal clinical study results supporting initial indication.
Today, Atmo Biosciences announced the publication of pivotal clinical study data in Clinical Gastroenterology and Hepatology. The study validates the Atmo Capsule for assessing whole and regional gastrointestinal transit times to assist with the diagnosis of motility disorders such as gastroparesis and slow transit constipation.
14 October 2024
Atmo awarded Stage 2 funding through ANDHealth+ program.
Atmo Biosciences is pleased to announce that it has been awarded funding through the ANDHealth+ Stage 2 Commercialization Program, aimed at helping five digital health companies scale their products nationally and internationally.
May 2, 2024
Atmo Gas Capsule used in Florida State University study assessing gastrointestinal impact of a fasting diet.
Atmo Biosciences’ ingestible gas-sensing capsule was used to assess the impact of an early-time restricted eating diet on gastrointestinal hydrogen production and gastrointestinal transit time.
April 9, 2024
Atmo Biosciences reaches primary endpoints in pivotal clinical study for initial indication.
Atmo Biosciences is delighted to report that it has successfully reached its primary endpoints in a pivotal clinical study to assess whole and regional gut transit time in subjects with suspected gastrointestinal motility disorders.
